Has Drew Barrymore confirmed she uses HRT?

Barrymore has confirmed she is experiencing perimenopause and has publicly discussed considering and exploring HRT. She has not disclosed a specific HRT regimen or confirmed ongoing use of a particular medication.

Which celebrities have confirmed using HRT?

Halle Berry, Oprah Winfrey, and Naomi Watts have all confirmed HRT use in public interviews or through their media platforms. Michelle Obama has discussed menopausal symptoms but has not confirmed or denied HRT use.

Is HRT safe for perimenopausal women?

For most symptomatic women under 60 or within 10 years of menopause onset, HRT is considered safe and effective according to the North American Menopause Society and the Endocrine Society. Individual risk factors (clotting history, breast cancer history, cardiovascular risk) must be assessed by a clinician.

What is the difference between bioidentical and synthetic HRT?

Bioidentical hormones (such as oral micronized progesterone and transdermal estradiol) are chemically identical to the hormones produced by the human body. Synthetic progestins (such as medroxyprogesterone acetate) have a different molecular structure. Some evidence suggests bioidentical progesterone may carry a lower breast cancer risk than synthetic progestins, though both are effective for endometrial protection.

How long does it take for HRT to work?

Most women notice improvement in vasomotor symptoms (hot flashes, night sweats) within 2 to 4 weeks, with full effect typically reached by 3 months. Genitourinary symptoms may take longer, often 8 to 12 weeks with local estrogen therapy.

Drew Barrymore Compared to Other Public Women's HRT Figures

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Drew Barrymore's Public HRT Record

Drew Barrymore brought perimenopause into daytime television by discussing her own experience on The Drew Barrymore Show. She described weight fluctuations, mood changes, and the emotional toll of hormonal shifts during her late 40s. In multiple on-air segments and print interviews, she confirmed she was actively considering and exploring hormone replacement therapy as part of managing her symptoms.

Her willingness to discuss these topics on a mainstream platform is significant. Perimenopause affects roughly 1.3 million women annually in the United States alone, yet public conversation about treatment options has historically been muted by stigma and confusion left over from early, now-revised findings of the Women's Health Initiative (WHI).

What sets Barrymore's disclosure apart is its format: unscripted, emotional, and aimed squarely at a general audience rather than a health-focused outlet.

At a glance

Status: Confirmed. Barrymore has publicly discussed perimenopause symptoms and HRT consideration on her talk show and in interviews.
Drug family: Women's HRT (estrogen, progesterone, and combination formulations).
Timeline: Disclosures began during the 2022-2024 seasons of The Drew Barrymore Show.
Reported outcomes: Barrymore has spoken about weight changes, mood shifts, and an evolving understanding of her hormonal health. She has not publicly detailed a specific HRT regimen or brand.

The Celebrity HRT Disclosure Pattern

Barrymore is one of several prominent women who have spoken about menopause and HRT in recent years. Comparing these disclosures reveals consistent themes and a few important differences.

Halle Berry has been one of the most vocal advocates. Berry confirmed she entered perimenopause in her early 40s and has publicly lobbied for menopause research funding, including testifying before the U.S. Congress. She has confirmed using HRT and described it as a turning point in managing her symptoms.

Naomi Watts launched a menopause-focused wellness brand (Stripes) and has confirmed entering perimenopause at 36. Watts has discussed her initial misdiagnosis and the years she spent without proper treatment before finding a regimen that worked for her.

Oprah Winfrey publicly confirmed using hormone replacement therapy and customized bioidentical hormones. In her magazine and on her platform, Winfrey described the process of working with her physician to find the right combination, including estradiol and progesterone.

Michelle Obama discussed menopause symptoms, including hot flashes, in her memoir and in interviews. She has acknowledged the hormonal transition publicly but has not confirmed or denied specific HRT use.

Gwyneth Paltrow has discussed perimenopause through her Goop platform and has spoken about considering HRT, though her specific regimen has not been fully confirmed in public interviews.

Disclosure Comparison Table

| Celebrity | Confirmed HRT Use | Public Since | Primary Platform | Specific Regimen Disclosed | |---|---|---|---|---| | Drew Barrymore | HRT consideration confirmed | ~2022 | Talk show, interviews | No | | Halle Berry | Yes, confirmed | ~2021 | Interviews, Congressional testimony | Partial | | Naomi Watts | Yes, confirmed | ~2022 | Interviews, brand launch | No | | Oprah Winfrey | Yes, confirmed | ~2009 | Magazine, TV | Partial (bioidenticals) | | Michelle Obama | Menopause confirmed; HRT not confirmed | ~2022 | Memoir, interviews | No | | Gwyneth Paltrow | HRT consideration discussed | ~2022 | Goop, interviews | No |

The pattern is clear. Most public disclosures cluster around 2021-2024, suggesting a cultural shift rather than isolated acts. The women who disclosed earliest (Winfrey) did so to smaller audiences with less clinical detail. More recent disclosures (Berry, Barrymore) have been louder, more specific, and more politically engaged.

Clinical Context: What Is Women's HRT?

Hormone replacement therapy for menopausal and perimenopausal women typically involves estrogen alone (for women without a uterus) or estrogen combined with a progestogen (for women with an intact uterus, to prevent endometrial hyperplasia).

Common formulations include:

Oral estradiol: 0.5 mg to 2 mg daily. The most widely prescribed systemic estrogen.
Transdermal estradiol patches: 25 to 100 mcg, applied once or twice weekly. Preferred in women with elevated cardiovascular or thromboembolic risk because they bypass first-pass liver metabolism (The Lancet, 2019).
Oral micronized progesterone: 100 to 200 mg nightly for 12-14 days per month (cyclic) or 100 mg nightly (continuous). Used for endometrial protection and, in some women, sleep support.
Vaginal estrogen: Low-dose creams, rings, or tablets for urogenital symptoms.

Mechanism of Action

Estrogen replacement addresses the primary hormonal deficit of menopause. Declining estradiol production by the ovaries drives vasomotor symptoms (hot flashes, night sweats), genitourinary atrophy, sleep disruption, and accelerated bone loss. Exogenous estradiol binds estrogen receptors (ER-alpha and ER-beta) across multiple tissues, restoring thermoregulatory stability, vaginal mucosal integrity, and bone mineral density.

Progesterone counterbalances the proliferative effects of estrogen on the endometrium. Without it, unopposed estrogen significantly increases the risk of endometrial cancer.

Benefits Supported by Evidence

The 2022 position statement from The North American Menopause Society (NAMS) reaffirmed that HRT remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause. Additional documented benefits include:

Reduction in hot flash frequency by 75% or more in most women
Prevention of osteoporotic fractures, as demonstrated in the WHI and subsequent analyses
Improvement in sleep quality, particularly with evening progesterone dosing
Potential reduction in all-cause mortality when initiated within 10 years of menopause onset (the "timing hypothesis," supported by data from the Danish Osteoporosis Prevention Study)

Risks and Side Effects

HRT is not without risk. The original WHI trial raised concerns about breast cancer, stroke, and venous thromboembolism (VTE). Subsequent reanalysis has refined this picture considerably:

Breast cancer: Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk after approximately 5 years of use. Estrogen-only therapy showed no increased risk, and possibly a decreased risk, in the WHI's long-term follow-up.
VTE: Oral estrogen increases clotting risk. Transdermal estrogen does not appear to carry the same risk, making route of administration a critical clinical decision.
Stroke: Slightly elevated risk with oral formulations, particularly in older women who initiate HRT more than 10 years after menopause.
Common side effects: Breast tenderness, bloating, headaches, and irregular bleeding (typically during the first 3-6 months).

Contraindications

HRT is generally contraindicated in women with a history of breast cancer, active liver disease, unexplained vaginal bleeding, or a history of venous thromboembolism. Individual risk assessment with a knowledgeable clinician remains essential.

What the Celebrity Disclosure Wave Teaches the Field

The HealthRX Medical Team sees three clinical takeaways from the pattern of celebrity HRT disclosures.

First, visibility reduces diagnostic delay. The average woman waits years between the onset of perimenopausal symptoms and receiving appropriate treatment. Public figures describing their own delayed diagnoses (Watts, Berry) give patients language and permission to push for earlier evaluation. A 2023 survey found that nearly 75% of menopausal women go untreated for their symptoms, often because they do not recognize the connection to hormonal changes or because their clinicians do not raise the topic.

Second, not all disclosures carry equal clinical value. Barrymore's discussion of symptoms and treatment consideration is directionally helpful, but it stops short of the specificity that Berry or Winfrey have offered. From a public health standpoint, the most useful disclosures are those that normalize the medical encounter itself (seeing a specialist, getting bloodwork, discussing formulations) rather than simply acknowledging symptoms exist.

Third, the WHI shadow persists. Even among informed public figures, there is visible hesitation around HRT. Some celebrities discuss "considering" or "exploring" HRT rather than confirming use, reflecting the residual fear from the 2002 WHI headlines that overstated the risks and led to a generation of women avoiding effective treatment. Two decades of follow-up data have substantially changed the risk-benefit calculus, particularly for women under 60 or within 10 years of menopause.

The HealthRX Medical Team Take

Drew Barrymore's contribution to the public HRT conversation is valuable, even if it lacks the clinical specificity of Halle Berry's advocacy or Oprah Winfrey's detailed regimen disclosures. Her platform reaches women who may not follow health-specific media, and her emotional openness about perimenopause symptoms helps reduce the shame that still surrounds this normal biological transition.

The collective picture across these celebrity disclosures mirrors what the clinical data already supports: HRT is underutilized, frequently delayed, and often avoided due to outdated risk perceptions rooted in the initial WHI interpretation. The 2024 Endocrine Society guidelines continue to support individualized HRT for symptomatic women within the appropriate window.

For patients watching these conversations unfold in media, the message from the HealthRX Medical Team is simple. Celebrity disclosures are a starting point, not a treatment plan. The right HRT regimen depends on your age, time since menopause, personal and family medical history, and symptom profile. Work with a menopause-trained clinician. Get baseline mammography and cardiovascular risk assessment. And know that the science has moved well beyond the fear that dominated the early 2000s.

Frequently asked questions

›